RxDoctor Payments Data

Angela Tschosik-Johnson, APRN

Nurse Practitioner · Sterling, ILNPI 1811665185

Payments from drug & device makers

$802in general payments, 2019–2025

Across 34 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$233
  • Regeneron Healthcare Solutions, Inc.$139
  • Philips North America LLC$88
  • Otsuka America Pharmaceutical, Inc.$58
  • Novo Nordisk$46
  • Boehringer Ingelheim$42
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$71289%
  • Education$9011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$802 in reported general payments places this provider in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$40,431
Medicare patients
219
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter496$348,391
ZemairaAlpha-1-Proteinase Inhibitor13$143,963
Breztri AerosphereBudesonide/Glycopyr/Formoterol112$84,268
Breo ElliptaFluticasone/Vilanterol78$39,626
Spiriva RespimatTiotropium Bromide51$37,737
SymbicortBudesonide/Formoterol Fumarate85$24,075
Incruse ElliptaUmeclidinium Bromide40$14,324
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$13,188
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate41$11,161
Albuterol Sulfate HfaAlbuterol Sulfate348$7,834
Atrovent HfaIpratropium Bromide11$5,740
Roflumilast26$5,549
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,521
Spiriva HandihalerTiotropium Bromide11$5,357
DuleraMometasone/Formoterol14$4,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$41$415,529642 claims
AstraZenecaBreztri Aerosphere, Symbicort$233$108,343197 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$42$43,25862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Sterling

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →